Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy

ClinicalTrials.gov ID: NCT00003010

Public ClinicalTrials.gov record NCT00003010. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 22, 2026, 9:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After Induction Chemotherapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Marimastat may stop the growth of breast cancer by stopping blood flow to the tumor. It is not known whether chemotherapy is more effective with or without marimastat for breast cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of marimastat with that of no further therapy in treating women who have metastatic breast cancer that is responding or stable after chemotherapy.

Study identification

NCT ID
NCT00003010
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
334 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 120 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 1, 1997
Primary completion
Nov 30, 2004
Completion
Not listed
Last update posted
Jun 14, 2023

Started 1997

United States locations

U.S. sites
25
U.S. states
12
U.S. cities
25
Facility City State ZIP Site status
CCOP - Scottsdale Oncology Program Scottsdale Arizona 85259-5404
Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago Illinois 60611
CCOP - Carle Cancer Center Urbana Illinois 61801
CCOP - Cedar Rapids Oncology Project Cedar Rapids Iowa 52403-1206
CCOP - Iowa Oncology Research Association Des Moines Iowa 50309-1016
Siouxland Hematology-Oncology Sioux City Iowa 51101-1733
CCOP - Wichita Wichita Kansas 67214-3882
CCOP - Duluth Duluth Minnesota 55805
Mayo Clinic Cancer Center Rochester Minnesota 55905
CentraCare Clinic Saint Cloud Minnesota 56303
CCOP - Missouri Valley Cancer Consortium Omaha Nebraska 68131
Trinitas Hospital - Jersey Street Campus Elizabeth New Jersey 07201
Hunterdon Regional Cancer Center Flemington New Jersey 08822
Hackensack University Medical Center Hackensack New Jersey 07601
Morristown Memorial Hospital Morristown New Jersey 07962-1956
Riverview Medical Center Red Bank New Jersey 07701
St. Francis Medical Center Trenton New Jersey 08629
Albert Einstein Comprehensive Cancer Center The Bronx New York 10461
Medcenter One Health System Bismarck North Dakota 58501
Altru Health Systems Grand Forks North Dakota 58201
CCOP - Columbus Columbus Ohio 43206
CCOP - Toledo Community Hospital Oncology Program Toledo Ohio 43623-3456
Hahnemann University Hospital Philadelphia Pennsylvania 19102-1192
Rapid City Regional Hospital Rapid City South Dakota 57709
CCOP - Sioux Community Cancer Consortium Sioux Falls South Dakota 57105-1080

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00003010, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 14, 2023 · Synced Sep 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00003010 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →